FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085655131> ?p ?o ?g. }

• W2085655131 endingPage "266" @default.
• W2085655131 startingPage "261" @default.
• W2085655131 abstract "Background In vitro experimental studies showed that A2a receptor agonists reduce allostimulatory functions of the dendritic cells through modulation of surface expression of the costimulatory molecules and down-regulation of cytokines. Similar suppressive effects on dendritic cells have also been observed with Cyclosporine A (CsA). In this study we sought to explore if combined use of these two drugs in vivo could prolong the survival of composite tissue allografts across MHC barriers. Materials and methods A total of 24 hindlimb transplantations were performed across a major MHC barrier from Brown Norway rats (BN; RT1n) to Lewis rats (Lew; RT1l) In the control group, either isografts (group 1, n = 2) or allografts (group 2, n = 3) were performed and no treatment was given. In the experimental group three kinds of treatment protocols were used: (1) A2a adenosine receptor agonist alone (group 3, n = 6); (2) CsA alone (group 4, n = 7); and (3) A2a adenosine receptor agonist + CsA combined treatment (group 5, n = 6). Mean survival times of each group as well as cytokine levels including IL-2, IL-4, IL-10, INF-γ, and TNF-α were analyzed by ELISA. Results Isografts survived indefinitely. The mean survival times for allograft groups (group 2 to 5) were 9.8 ± 1.3, 10.5 ± 1.0, 29.8 ± 1.7, and 22 ± 1.4 days, respectively. Statistically, there was no difference between the allograft control group and the A2a adenosine receptor agonist treated group (P = 0.35). However, survival of the allografts in the CsA-treated group was significantly higher than the A2a adenosine receptor agonist treated (P < 00001) and combined CsA + A2a adenosine receptor agonist treated group (P < 0.0001). In vivo A2a adenosine receptor agonist treatment alone increased the levels of IL-2, INF-γ, and TNF-α, which are important cytokines for induction of allotransplant rejection. However A2a adenosine receptor agonist in combination with CsA significantly reduced the levels of suppressor cytokines IL-4 and IL-10. Conclusion As opposed to the previous in vitro studies, the results from this in vivo study showed that A2a adenosine receptor agonist treatment does not prolong composite tissue allograft survival. Compared to CsA treatment alone, the allotransplant survival was even shorter with the combined treatment. Treatment with A2a adenosine receptor agonist possibly promotes the differentiation of alloreactive CD4 cells predominantly into T-helper 1 phenotype. As a result, the levels of stimulatory cytokines contributing to allograft rejection are increased and suppressor cytokines are reduced, leading to accelerated allograft rejection. In vitro experimental studies showed that A2a receptor agonists reduce allostimulatory functions of the dendritic cells through modulation of surface expression of the costimulatory molecules and down-regulation of cytokines. Similar suppressive effects on dendritic cells have also been observed with Cyclosporine A (CsA). In this study we sought to explore if combined use of these two drugs in vivo could prolong the survival of composite tissue allografts across MHC barriers. A total of 24 hindlimb transplantations were performed across a major MHC barrier from Brown Norway rats (BN; RT1n) to Lewis rats (Lew; RT1l) In the control group, either isografts (group 1, n = 2) or allografts (group 2, n = 3) were performed and no treatment was given. In the experimental group three kinds of treatment protocols were used: (1) A2a adenosine receptor agonist alone (group 3, n = 6); (2) CsA alone (group 4, n = 7); and (3) A2a adenosine receptor agonist + CsA combined treatment (group 5, n = 6). Mean survival times of each group as well as cytokine levels including IL-2, IL-4, IL-10, INF-γ, and TNF-α were analyzed by ELISA. Isografts survived indefinitely. The mean survival times for allograft groups (group 2 to 5) were 9.8 ± 1.3, 10.5 ± 1.0, 29.8 ± 1.7, and 22 ± 1.4 days, respectively. Statistically, there was no difference between the allograft control group and the A2a adenosine receptor agonist treated group (P = 0.35). However, survival of the allografts in the CsA-treated group was significantly higher than the A2a adenosine receptor agonist treated (P < 00001) and combined CsA + A2a adenosine receptor agonist treated group (P < 0.0001). In vivo A2a adenosine receptor agonist treatment alone increased the levels of IL-2, INF-γ, and TNF-α, which are important cytokines for induction of allotransplant rejection. However A2a adenosine receptor agonist in combination with CsA significantly reduced the levels of suppressor cytokines IL-4 and IL-10. As opposed to the previous in vitro studies, the results from this in vivo study showed that A2a adenosine receptor agonist treatment does not prolong composite tissue allograft survival. Compared to CsA treatment alone, the allotransplant survival was even shorter with the combined treatment. Treatment with A2a adenosine receptor agonist possibly promotes the differentiation of alloreactive CD4 cells predominantly into T-helper 1 phenotype. As a result, the levels of stimulatory cytokines contributing to allograft rejection are increased and suppressor cytokines are reduced, leading to accelerated allograft rejection." @default.
• W2085655131 created "2016-06-24" @default.
• W2085655131 creator A5043049964 @default.
• W2085655131 creator A5077762672 @default.
• W2085655131 creator A5086617658 @default.
• W2085655131 creator A5087737852 @default.
• W2085655131 date "2006-04-01" @default.
• W2085655131 modified "2023-09-30" @default.
• W2085655131 title "The Effect of A2A Adenosine Receptor Agonist on Composite Tissue Allotransplant Survival: An In Vivo Preliminary Study" @default.
• W2085655131 cites W1547923771 @default.
• W2085655131 cites W161060649 @default.
• W2085655131 cites W1661544713 @default.
• W2085655131 cites W1898549991 @default.
• W2085655131 cites W1983877307 @default.
• W2085655131 cites W1990113288 @default.
• W2085655131 cites W2002386322 @default.
• W2085655131 cites W2007398214 @default.
• W2085655131 cites W2012461372 @default.
• W2085655131 cites W2012568607 @default.
• W2085655131 cites W2013820979 @default.
• W2085655131 cites W2018347811 @default.
• W2085655131 cites W2031462278 @default.
• W2085655131 cites W2042645266 @default.
• W2085655131 cites W2044750544 @default.
• W2085655131 cites W2045073952 @default.
• W2085655131 cites W2049053823 @default.
• W2085655131 cites W2070960562 @default.
• W2085655131 cites W2077884399 @default.
• W2085655131 cites W2090128233 @default.
• W2085655131 cites W2102732638 @default.
• W2085655131 cites W2129667982 @default.
• W2085655131 cites W2130447231 @default.
• W2085655131 cites W2162336293 @default.
• W2085655131 cites W2172047118 @default.
• W2085655131 doi "https://doi.org/10.1016/j.jss.2005.12.016" @default.
• W2085655131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16457843" @default.
• W2085655131 hasPublicationYear "2006" @default.
• W2085655131 type Work @default.
• W2085655131 sameAs 2085655131 @default.
• W2085655131 citedByCount "4" @default.
• W2085655131 countsByYear W20856551312014 @default.
• W2085655131 countsByYear W20856551312017 @default.
• W2085655131 countsByYear W20856551312020 @default.
• W2085655131 crossrefType "journal-article" @default.
• W2085655131 hasAuthorship W2085655131A5043049964 @default.
• W2085655131 hasAuthorship W2085655131A5077762672 @default.
• W2085655131 hasAuthorship W2085655131A5086617658 @default.
• W2085655131 hasAuthorship W2085655131A5087737852 @default.
• W2085655131 hasConcept C126322002 @default.
• W2085655131 hasConcept C134018914 @default.
• W2085655131 hasConcept C150903083 @default.
• W2085655131 hasConcept C170493617 @default.
• W2085655131 hasConcept C17991360 @default.
• W2085655131 hasConcept C203014093 @default.
• W2085655131 hasConcept C207001950 @default.
• W2085655131 hasConcept C2776991684 @default.
• W2085655131 hasConcept C2778491162 @default.
• W2085655131 hasConcept C2778690821 @default.
• W2085655131 hasConcept C2778938600 @default.
• W2085655131 hasConcept C67907053 @default.
• W2085655131 hasConcept C71924100 @default.
• W2085655131 hasConcept C86803240 @default.
• W2085655131 hasConcept C98274493 @default.
• W2085655131 hasConceptScore W2085655131C126322002 @default.
• W2085655131 hasConceptScore W2085655131C134018914 @default.
• W2085655131 hasConceptScore W2085655131C150903083 @default.
• W2085655131 hasConceptScore W2085655131C170493617 @default.
• W2085655131 hasConceptScore W2085655131C17991360 @default.
• W2085655131 hasConceptScore W2085655131C203014093 @default.
• W2085655131 hasConceptScore W2085655131C207001950 @default.
• W2085655131 hasConceptScore W2085655131C2776991684 @default.
• W2085655131 hasConceptScore W2085655131C2778491162 @default.
• W2085655131 hasConceptScore W2085655131C2778690821 @default.
• W2085655131 hasConceptScore W2085655131C2778938600 @default.
• W2085655131 hasConceptScore W2085655131C67907053 @default.
• W2085655131 hasConceptScore W2085655131C71924100 @default.
• W2085655131 hasConceptScore W2085655131C86803240 @default.
• W2085655131 hasConceptScore W2085655131C98274493 @default.
• W2085655131 hasIssue "2" @default.
• W2085655131 hasLocation W20856551311 @default.
• W2085655131 hasLocation W20856551312 @default.
• W2085655131 hasOpenAccess W2085655131 @default.
• W2085655131 hasPrimaryLocation W20856551311 @default.
• W2085655131 hasRelatedWork W1978927254 @default.
• W2085655131 hasRelatedWork W2017770252 @default.
• W2085655131 hasRelatedWork W2026105695 @default.
• W2085655131 hasRelatedWork W2031254193 @default.
• W2085655131 hasRelatedWork W2031470785 @default.
• W2085655131 hasRelatedWork W2080915831 @default.
• W2085655131 hasRelatedWork W2087962024 @default.
• W2085655131 hasRelatedWork W2128990320 @default.
• W2085655131 hasRelatedWork W4252850006 @default.
• W2085655131 hasRelatedWork W90251224 @default.
• W2085655131 hasVolume "131" @default.
• W2085655131 isParatext "false" @default.
• W2085655131 isRetracted "false" @default.
• W2085655131 magId "2085655131" @default.
• W2085655131 workType "article" @default.